MYBPC3 rs1052373: Endurance and Cardiac Adaptation
The rs1052373 variant is a single-nucleotide polymorphism located within the MYBPC3 gene on chromosome 11. Research has linked this variant to aerobic capacity, endurance athletic status, and exercise-induced cardiac remodeling. Classified generally as benign in clinical databases, it represents a common polymorphism rather than a causative disease mutation.
What each genotype means
Enhanced endurance potential
Research suggests this genotype is associated with elite endurance athlete status and may influence exercise-induced cardiac remodeling. While these findings are statistically significant in some cohorts, athletic performance is complex and influenced by many genetic and environmental factors.
The G allele is common, with the GG genotype appearing in a significant portion of European populations.
Intermediate endurance profile
Carrying one copy of the G allele may contribute to the physiological traits associated with endurance performance, though the effect is typically less pronounced than in those with two copies. This variant is studied for its role in aerobic capacity, but it does not determine athletic success on its own.
This heterozygous genotype is frequently observed in populations where the G allele is common.
Baseline endurance profile
This genotype represents the alternative state at this position, which has been less strongly associated with the specific endurance-related phenotypes identified in some elite athlete studies. Individual athletic potential remains highly dependent on training, nutrition, and a wide range of other genetic markers.
The AA genotype is present in a substantial segment of the population, though frequency varies by ancestry.
Variant Classification and Molecular Location
The single-nucleotide polymorphism rs1052373 is situated within the MYBPC3 gene, located on chromosome 11p11.2. At the DNA level, this polymorphism typically presents as an exchange between an adenine (A) and a guanine (G) nucleotide. When transcribed and translated, this missense change results in an amino acid substitution of serine by glycine at residue position 236 (p.Ser236Gly). While the MYBPC3 gene is heavily screened in cardiovascular medicine due to its known association with inherited heart conditions, public repositories like ClinVar consistently catalog rs1052373 as benign or likely benign regarding pathology. Rather than predisposing carriers to genetic heart failure or dangerous cardiomyopathy, this common variant is viewed as a naturally occurring variation. Researchers focus on rs1052373 primarily as a marker that may influence how cardiac sarcomeres adapt under chronic physical training regimens.
Biological Function of the MYBPC3 Gene
The MYBPC3 gene encodes cardiac myosin-binding protein C (cMyBP-C), a structural protein expressed in striated heart muscle cells. Within the sarcomere—the fundamental contractile unit of striated muscle—cMyBP-C stabilizes the thick filaments composed of myosin and interacts dynamically with actin thin filaments. This protein acts like a biological brake and regulator, orchestrating the velocity of cross-bridge cycling and ensuring uniform contraction and relaxation of the cardiac ventricles during the cardiac cycle. Pathogenic loss-of-function or truncating mutations in MYBPC3 are well established as the most frequent primary cause of familial hypertrophic cardiomyopathy. However, milder or common variants such as rs1052373 alter the protein without abolishing its basic structural scaffolding, potentially modifying mechanical compliance or cardiac remodeling pathways in response to sustained aerobic training loads.
Association with Athletic Endurance and VO2 Max
Scientific interest in rs1052373 as a performance marker gained significant traction following a large-scale genome-wide association study (GWAS) investigating elite athletic status. In cohorts of European and Russian athletes, meta-analyses identified the rs1052373 G allele as being enriched among individuals competing in disciplines requiring high aerobic endurance compared to low-to-moderate aerobic disciplines. Homozygous carriers of the G allele (GG) exhibited significantly higher maximal oxygen uptake (VO2 max) in physiological evaluations than carriers of the A allele. Subsequent metabolomic evaluations identified distinct amino acid and lipid profiles tied to this genotype, including steroid intermediates involved in physical exertion. While these findings achieve statistical significance in specific cohorts, replication across diverse global athletic groups remains ongoing, classifying the overall predictive evidence strength as moderate.
Exercise-Induced Cardiac Remodeling vs. Pathology
High-intensity athletic training naturally provokes cardiac remodeling, commonly recognized as 'athlete's heart.' This physiological phenomenon entails adaptive left ventricular hypertrophy, increased chamber compliance, and expanded stroke volume to accommodate high cardiac outputs. Because severe, disruptive mutations in MYBPC3 trigger pathological hypertrophy, researchers have hypothesized that common variations like rs1052373 could calibrate how heart muscle hypertrophies adaptively under rigorous physical training. Unlike pathological hypertrophic cardiomyopathy, physiological athlete's heart is a healthy, reversible response characterized by normal or enhanced diastolic function and no disarray of myofibrils. Current evidence suggests that rs1052373 may modulate exercise-induced adaptation without inducing structural pathology, though deeper mechanistic studies are still required to chart the exact cellular pathways involved.
Practical Interpretation and Everyday Applications
Discovering one's genotype at rs1052373 provides interesting biological insight into sarcomere variation, but it carries clear practical boundaries. Having the endurance-associated GG genotype does not guarantee elite aerobic capacity or athletic success, as endurance performance is a polygenic trait governed by hundreds of interacting loci, systemic training, nutrition, and environmental factors. Conversely, carrying the AA or AG genotype does not preclude anyone from building excellent cardiovascular fitness and reaching personal endurance milestones. Crucially, this variant is not a diagnostic marker for heart conditions, nor does it serve as medical guidance for cardiac risk. Anyone experiencing symptoms such as unexplained chest pain, lightheadedness, or palpitations should seek professional cardiovascular evaluation irrespective of common fitness-associated genetic findings.
How common is this variant?
The minor allele frequency for rs1052373 is approximately 0.35 in European populations, with the alternative allele being widely distributed across various global ancestral groups.
Frequently asked questions
Does carrying the rs1052373 G allele guarantee athletic success?
No. Elite athletic performance is an intensely polygenic trait influenced by thousands of genetic variants alongside rigorous training, nutrition, psychological factors, and recovery. While the G allele has shown statistical association with higher aerobic capacity in study cohorts, it explains only a small fraction of overall performance variance.
Is MYBPC3 rs1052373 linked to heart disease?
No. Although severe mutations in the MYBPC3 gene are a leading cause of hypertrophic cardiomyopathy, rs1052373 is classified as benign or likely benign in clinical databases like ClinVar. It is regarded as a normal human polymorphism rather than a causal pathogenic defect.
What is the difference between athlete's heart and hypertrophic cardiomyopathy?
Athlete's heart is a healthy, reversible physiological adaptation that increases chamber volume and muscle wall thickness to meet aerobic demands. In contrast, hypertrophic cardiomyopathy is a pathological disease involving chaotic heart muscle disarray, impaired diastolic relaxation, and elevated clinical risk.
Can I use this genetic test to design my workout routine?
Genetic results for rs1052373 should not be used to restrict or dictate your fitness choices. Both carriers and non-carriers can develop substantial aerobic endurance and cardiovascular health through evidence-based, progressive exercise regimens.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1052373?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MYBPC3
A common founder mutation (c.2827-2851del25) in the MYBPC3 gene strongly associated with hypertrophic cardiomyopathy in South Asian populations.
Pathogenic variant associated with hypertrophic cardiomyopathy.
Well-characterized founder variant (p.Pro955His) conferring autosomal dominant predisposition to adult-onset hypertrophic cardiomyopathy.
A well-known pathogenic variant associated with Hypertrophic Cardiomyopathy, which causes thickening of the heart muscle.